COMPANY
Lucier Pharmaceuticals Inc.
Lucier Pharmaceuticals is developing drug candidates for coronary microvascular dysfunction. Source · checked Oct 14, 2026
Sourced facts
Funding (SEC filing)
- SEC Form D filed Oct 13, 2026: amount sold not stated · sec.gov · checked Oct 14, 2026
Funding and NIH signals
- SEC Form D raise Filed a Form D for an offering of up to $2M, no sales reported yet (filed Oct 13, 2026). SEC Form D 0002158290-26-000003 (Oct 13, 2026)
Evidence (1 event)
- Oct 13, 2026 · SEC Form D 0002158290-26-000003
Name of Issuer: LUCIER PHARMACEUTICALS INC; CIK: 2158290; Address: Bryan, TX; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Other (SAFE (Simple Agreement for Future Equity), which does not grant immediate equity or voting rights.); Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 0; Federal exemptions: 06b
- Oct 13, 2026 · SEC Form D 0002158290-26-000003
- NIH award NIH awarded $606K (STTR Phase I 1R41HL184579-01A1, new, notice Sep 11, 2026). NIH RePORTER 1R41HL184579-01A1 (Sep 11, 2026)
Evidence (1 event)
- Sep 11, 2026 · NIH RePORTER 1R41HL184579-01A1
Organization: LUCIER PHARMACEUTICALS INC; City/State: CYPRESS, TX; Project number: 1R41HL184579-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 606311; Administering IC: National Heart Lung and Blood Institute; Project title: Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunction; Organization type: Domestic For-Profits
- Sep 11, 2026 · NIH RePORTER 1R41HL184579-01A1